
    
      An Open-Label Study of Poly I: Poly C12U (AmpligenÂ®) in Patients with Severely Debilitating
      Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME). The FDA approved the study for
      cost recovery. Patients enrolled in the study are responsible for costs related to the
      therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory
      testing.
    
  